07.16.21
Headquarters: Cambridge, MA
twitter.com/biogen
www.biogen.com
Headcount: 9,100
Year Established: 1986
Revenues: $13,445 (-7%)
Net Income: $4,001 (-32%)
R&D: $3,991 (+75%)
TOP SELLING DRUGS
Biogen, focused on innovative therapies for serious neurological and neurodegenerative diseases, as well as related therapeutic adjacencies, has 10 programs either in Phase 3 or filed with regulatory agencies, including in Alzheimer’s disease, neuropsychiatry, amyotrophic lateral sclerosis (ALS) and ophthalmology.
In 2020, the company added or advanced 12 clinical programs, bolstering its early- and late-stage pipelines through both internal development and collaborations.
In March 2020, Biogen acquired BIIB118 (CK1 inhibitor), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of behavioral and neurological symptoms across various psychiatric and neurological diseases, from Pfizer. The company is developing BIIB118 for the potential treatment of irregular sleep wake rhythm disorder (ISWRD) in Parkinson’s disease and plans to develop BIIB118 for the potential treatment of sundowning in Alzheimer's disease.
In April 2020 Biogen closed a collaboration and license agreement with Sangamo Therapeutics, Inc. to develop and commercialize ST-501 for tauopathies, including Alzheimer’s disease; ST-502 for synucleinopathies, including, Parkinson’s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo's proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases.
Biogen also closed a collaboration and license agreement with Denali Therapeutics to co-develop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease. In addition to the LRRK2 program, it also has an exclusive option to license two preclinical programs from Denali’s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled antiamyloid beta (Abeta) program and a second program utilizing its Transport Vehicle technology. Further, Biogen has a right of first negotiation on two additional Transport Vehicle-enabled therapeutics.
In December 2020 Biogen closed a global collaboration and license agreement with Sage Therapeutics, Inc. to jointly develop and commercialize zuranolone for the potential treatment of major depressive disorder, postpartum depression and other psychiatric disorders, and SAGE-324 for the potential treatment of essential tremor and other neurological disorders.
Of Biogen’s advancing assets, the EMA accepted for review the MAA for SB11, and the FDA accepted the BLA for SB11. Biogen has exclusive rights to commercialize SB11 in major markets pursuant to its 2019 agreement with Samsung Bioepis. SB11 is a proposed ranibizumab biosimilar referencing Lucentis.
Possibly the biggest news of the last year was the recent FDA approval of aducanumab, the first novel therapy for Alzheimer’s disease approved since 2003. Biogen and Japanese partner Eisai developed aducanumab, administered through intravenous infusion to treat early Alzheimer's disease. The drug was developed for mild cognitive impairment, not severe dementia.
twitter.com/biogen
www.biogen.com
Headcount: 9,100
Year Established: 1986
Revenues: $13,445 (-7%)
Net Income: $4,001 (-32%)
R&D: $3,991 (+75%)
TOP SELLING DRUGS
| Drug | Indication | 2020 Sales | (+/-%) |
| Fumarate | multiple sclerosis | $3,905 | -12% |
| Spinraza | Spinal muscular atrophe | $2,052 | -2.1 |
| TYSABRI | multiple sclerosis | $1,946 | 3% |
| Interferon | multiple sclerosis | $1,878 | -11 |
| BENEPALI | Arthritis, psoriasis | $482 | -1% |
| IMRALDI | Arthritis, rheumatoid | $216 | 18% |
| FAMPYRA | Multiple sclerosis | $103 | 6% |
| FLIXABI | Arthritis, rheumatoid | $98 | 43% |
| FUMADERM | Psoriasis | $12 | -20% |
Biogen, focused on innovative therapies for serious neurological and neurodegenerative diseases, as well as related therapeutic adjacencies, has 10 programs either in Phase 3 or filed with regulatory agencies, including in Alzheimer’s disease, neuropsychiatry, amyotrophic lateral sclerosis (ALS) and ophthalmology.
In 2020, the company added or advanced 12 clinical programs, bolstering its early- and late-stage pipelines through both internal development and collaborations.
In March 2020, Biogen acquired BIIB118 (CK1 inhibitor), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of behavioral and neurological symptoms across various psychiatric and neurological diseases, from Pfizer. The company is developing BIIB118 for the potential treatment of irregular sleep wake rhythm disorder (ISWRD) in Parkinson’s disease and plans to develop BIIB118 for the potential treatment of sundowning in Alzheimer's disease.
In April 2020 Biogen closed a collaboration and license agreement with Sangamo Therapeutics, Inc. to develop and commercialize ST-501 for tauopathies, including Alzheimer’s disease; ST-502 for synucleinopathies, including, Parkinson’s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo's proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases.
Biogen also closed a collaboration and license agreement with Denali Therapeutics to co-develop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease. In addition to the LRRK2 program, it also has an exclusive option to license two preclinical programs from Denali’s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled antiamyloid beta (Abeta) program and a second program utilizing its Transport Vehicle technology. Further, Biogen has a right of first negotiation on two additional Transport Vehicle-enabled therapeutics.
In December 2020 Biogen closed a global collaboration and license agreement with Sage Therapeutics, Inc. to jointly develop and commercialize zuranolone for the potential treatment of major depressive disorder, postpartum depression and other psychiatric disorders, and SAGE-324 for the potential treatment of essential tremor and other neurological disorders.
Of Biogen’s advancing assets, the EMA accepted for review the MAA for SB11, and the FDA accepted the BLA for SB11. Biogen has exclusive rights to commercialize SB11 in major markets pursuant to its 2019 agreement with Samsung Bioepis. SB11 is a proposed ranibizumab biosimilar referencing Lucentis.
Possibly the biggest news of the last year was the recent FDA approval of aducanumab, the first novel therapy for Alzheimer’s disease approved since 2003. Biogen and Japanese partner Eisai developed aducanumab, administered through intravenous infusion to treat early Alzheimer's disease. The drug was developed for mild cognitive impairment, not severe dementia.
